StoneWise operates a platform that combines a molecular design software module with a knowledge-graph driven approach to accelerate small‑molecule drug discovery. The company says its dual-engine (molecular design platform + knowledge graph) has been validated across multiple projects, including first-in-class and fast-follow programs and difficult targets such as disordered proteins. Its molecular design software is described as the first domestically commercialized AI drug-molecule design product and has been procured by multiple top research institutions and pharmaceutical companies. StoneWise reports that some collaborations produced breakthrough experimental results and helped partners realize hundreds of millions of dollars in downstream commercial value. The company plans to use new funding to recruit global talent, accelerate AI technology iteration, and consolidate industrialization and platform deployment. StoneWise was founded in 2018 and emphasizes continued partnerships and product-led expansion in early drug discovery. Founded in 2018, 望石智慧 develops an AI platform for early drug discovery that covers knowledge mining, scaffold discovery and selection, molecular generation and design, and property prediction. Its two core products are an intelligent molecular design platform for scaffold-based generation and optimization, and a knowledge graph integrating billions of data points on diseases, targets, and small molecules. The team blends AI, computational chemistry, and computational biology expertise and has partnerships with listed innovators and top research institutes, including BeyondSpring, Peking University Medical School, and the Chinese Academy of Medical Sciences. The company operates and conducts R&D in both China and the U.S., and is recruiting senior scientific and management talent to accelerate industrial integration. Technically it focuses on improving underlying algorithms (reinforcement learning, autoencoder networks, quantum chemistry integration) to raise barriers and enable wider pharma adoption. Financially, the company recently completed a near-$10M Series A financing to support platform iteration and market expansion.

Total raised

$100M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2021